Mirum Pharmaceuticals reports positive results from Cohort 2 of pivotal PROGRESS study of ATEBRIOZ in pediatric FOP patients

Mirum Pharmaceuticals announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ in pediatric patients aged 6 to <12 years with Fibrodysplasia Ossificans Progressiva (FOP). The company disclosed the study outcome in a company announcement.

Detected & updated continuously · Source: Nebula